Genetic Leap inks deal with Lilly on genetic meds development with AI

New York-based Genetic Leap, an AI-native techbio company innovating at the cutting edge of Artificial Intelligence and RNA genetic medicine, today announced a research collaboration with US pharma major Eli Lilly (NYSE: LLY) to develop genetic medicine therapeutics.

The collaboration builds on a successful pilot between the two companies and will leverage Genetic Leap's RNA-targeted AI platform to generate oligonucleotide drugs against targets selected by Lilly in high priority therapeutic areas.

The companies note that the central role of RNA in orchestrating essential biological processes holds significant potential to address critical diseases that traditional drugs have not been able to target effectively. Historically, drugging RNA has presented tremendous challenges. Genetic Leap's proprietary AI platform is revolutionizing the approach to drugging RNA.